Company profile

Company name
BIOMIMETICS SYMPATHIES Inc.
Date established
November 28, 2000
Profiles of our executives
Naoki Urushihata, Representative Director and Chairman
Keisuke Onishi, Representative Director and President
Kuo Chen, Director
Tetsuo Koike
Kazuharu Tomioka
Shigeo Jokura, Statutory auditor
Takashi Sueki (tax accountant)
Yoshiaki Oba (administrative scrivener)
Profiles of our executives

Keisuke Onishi, Representative Director and President

Received his Ph.D. from the School of Engineering in The University of Tokyo. Worked on his post-doctoral research in basic research in neuroscience at the University of California, San Diego from 2010 for 9 years. Joined the Research and Development Department of our company in 2019. Discovered a new therapeutic candidate for the treatment of COVID-19 at the end of January 2021. Appointed representative director and president of our company at the end of June 2023. Believes in the potential of regenerative medicine and is committed to developing new treatments to bring smiles to patients suffering from diseases, their families, and individuals around the world.

Kuo Chen, Director

Joined the Business Promotion Department of our company in 2019 and was assigned to international operations making use of being trilingual, speaking English, Chinese, and Japanese. As a core member of the China Joint Venture Project, led the establishment of the joint venture, Bloomage Concell Biotechnology (Hainan) Co., Ltd., in 2022 with 2 industry leading publicly listed companies in Japan and China. Was appointed a director of the joint venture and an executive officer of our company in the same year, in charge of the business in China. Appointed Director of our company in 2023 (to the present). In charge of the overall domestic and overseas business.

Capital
2.0333 billion JPY (as of March 2023)
Number of employees
18 (as of September 2023)
Business activities
  • Research and development and clinical development related to cell-based medicines
  • Licensing-out of products, intellectual property, and rights related to regenerative medicine
  • Development and marketing of cosmetics, reagents, and culture media based on regenerative medicine technology
  • Business development related to regenerative medicine
  • Business support for regenerative medicine
Address
Time 24 building, 19th floor, 2-4-32 Aomi, Koto-ku, Tokyo 135-0064
Contact information
Telephone no. 03-5500-6330/Fax 03-5500-6336
Legal advisor
Fairness Law Office
Uchida and Samejima Law Firm
Kurahashi Law Office

Access

Head Office
Time 24 building, 19th floor, 2-4-32 Aomi, Koto-ku, Tokyo 135-0064
By train
- 2-minute walk from “Telecom Center” station on the Yurikamome line
- 18-minute walk from “Tokyo Teleport” station on the Rinkai line
By car
- Please use the time-metered parking lot in the basement of our building.

Corporate history

2000
  • Started joint research with domestic and overseas research institutes such as Keio University and Monell Chemical Senses Center in the United States for early detection of cancer using dog from body odor and exhaled breath After conducting many studies, the technology was transferred. Later on focused on specializing in regenerative medicine.
2007
  • Embarked on work in regenerative medicine
  • Started development of animal origin free (AOF) culture technology for mesenchymal stem cells (MSC)
2008
  • Started CPF design and operation consulting for medical institutions
2011
  • Established high-quality MSC culture technology with our own AOF cell culture medium
  • Relocated office to the Odaiba area in Tokyo (current office)
  • Completed constructions and started operation of a large-scale CPF in the Odaiba area in Tokyo
  • Started activities to support regenerative medical technology for medical institutions
2013
  • Started joint research on regenerative medicine with Rohto Pharmaceutical Co., Ltd.
2014
  • Changed company name to BIOMIMETICS SYMPATHIES Inc.
2015
  • Obtained license as a cell-processing center
  • Started contract culture service compliant with the Act on the Safety of Regenerative Medicine
  • Established a laboratory for industry-academia collaboration at Tokyo Medical University (until March 2018)
2016
  • Started sales of raw materials for cosmetics
2019
  • Expanded culture media sales business
2020
  • Launched our own cosmetics
2021
  • Discovered and licensed out a candidate of therapeutic compounds for COVID-19 to Rohto Pharmaceutical Co., Ltd.
2022
  • Selected for AMED public offering “FY2022 Research Program on Emerging and Re-emerging Infectious Diseases”
  • Established a joint venture in Hainan, China, with several companies such as Bloomage Concell Biotechnology (Hainan) Co., Ltd. and Rohto Pharmaceutical Co., Ltd

Philosophy

Corporate philosophy

PHILOSOPHY

“The truth will set you free.”

Are the knowledge, truths, and habits we have correct and constant? Correct and constant knowledge sets people free.
We aim to contribute to society so that people can enjoy their inherent freedom in the medical field.

MISSION

MISSION

Bringing smiles to patients suffering from diseases, their families, and
individuals around the world through regenerative medicine

VISSION

VISSION

Creating healthcare that will pass down generation to generation

CREDO

We established the following guidelines on actions with the aim of bringing the happiness and health of society to fruition.

CREDO

We will provide Beatific, Merciful and
Superb healthcare services for the future.

  • We will always look for ways to bring happiness to patients, customers and employees.
  • We will always approach things with sincerity and face things head on.
  • We will continue to learn to be able to treat diseases.
  • We will continue to grow as individuals and as a company.
  • We aim to be a company that appreciates society and is loved by society.
  • We aim to bring reliable, safe, and inexpensive treatments all over the world.

* “Customers”: Current and future business partners